Impact of Immunotherapies on SARS-CoV-2-Infections and Other Respiratory Tract Infections during the COVID-19 Winter Season in IBD Patients

Table 2

IBD cohort characteristics by therapy.

	Patients without immunotherapy n (%)	Patients with immunotherapy n (%)	TNF-alpha blockers: infliximab, adalimumab, golimumab n (%)	Infliximab n (%)	Adalimumab n (%)	Ustekinumab n (%)	Vedolizumab n (%)	Immunotherapy combinations n (%)
Total number	249 (22.8)	842 (77.2)	475	370	95	154	146	45
CD	104 (41.8)	479 (56.9)	313 (65.9)	233 (63.0)	76 (83.2)	102 (66.2)	34 (23.3)	26 (57.8)
UC	145 (58.2)	363 (43.1)	162 (34.1)	137 (37.0)	16 (16.8)	52 (33.8)	112 (76.7)	19 (42.2)
Female	157 (63.1)	442 (52.5)	225 (47.4)	116 (45.1)	53 (55.8)	97 (63.9)	84 (57.5)	22 (48.9)
Median age	43.1 years, range 19–88	41.6 years, range 18–89	41.2 years, range 18–87	40.8 years, range 19–87	41.9 years, range 18–77	43.5 years, range 21–83	43.1 years, range 19–89	33.8 years, range 20–69
Median disease duration	140.5 months, range 0.5–580	148.6 months, range 0.5–650	141.6 months, range 0.5–650	135.1 months, range 0–650	169.5 months, range 10–471	168.0 months, range 10–556	150.5 months, range 10–448	160.8 months, range 7–519
Age >49 years	77 (30.9)	247 (29.3)	128 (27.0)	98 (26.5)	25 (26.3)	50 (32.5)	39 (26.7)	3 (6.7)